Hepatic fibrosis is a highly evolved response to tissue injury, with the liver being a well-studied example. The process involves the accumulation of extracellular matrix (ECM) components, primarily collagens, and is driven by the activation of hepatic stellate cells (HSCs), the main fibrogenic cells in the liver. HSCs, normally quiescent storage cells for retinoids, become activated in response to liver injury, transitioning into proliferative, fibrogenic, and contractile myofibroblasts. This activation is a complex, tightly regulated process involving both paracrine and autocrine signaling, as well as ECM remodeling. The activation of HSCs begins with initiation, characterized by changes in gene expression and phenotype, making the cells responsive to cytokines and other stimuli. This is followed by perpetuation, where enhanced cytokine expression and ECM remodeling sustain the activated phenotype. Key mediators include transforming growth factor-β1 (TGF-β1), which is central to ECM production and stellate cell activation. TGF-β1 is increased in liver fibrosis and is involved in both the initiation and perpetuation of fibrosis. HSC activation leads to a series of phenotypic responses, including proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis, retinoid loss, and cytokine release. These responses are mediated by various signaling pathways, including those involving receptor tyrosine kinases, integrins, and the discoidin domain receptor (DDR2). The activation of HSCs is also influenced by changes in the ECM composition, which shifts from a basement membrane-like matrix to an interstitial matrix rich in fibril-forming collagens. During liver injury, HSCs migrate to areas of injury and contribute to the accumulation of scar tissue. The resolution of liver fibrosis involves the reversion of activated HSCs to a quiescent state or their clearance via apoptosis. Understanding the molecular mechanisms of HSC activation and resolution is crucial for developing therapeutic strategies to treat liver fibrosis. The study of HSCs provides a model for understanding how complex cellular events are integrated to achieve a distinct biological outcome, the encapsulation of tissue injury by scar.Hepatic fibrosis is a highly evolved response to tissue injury, with the liver being a well-studied example. The process involves the accumulation of extracellular matrix (ECM) components, primarily collagens, and is driven by the activation of hepatic stellate cells (HSCs), the main fibrogenic cells in the liver. HSCs, normally quiescent storage cells for retinoids, become activated in response to liver injury, transitioning into proliferative, fibrogenic, and contractile myofibroblasts. This activation is a complex, tightly regulated process involving both paracrine and autocrine signaling, as well as ECM remodeling. The activation of HSCs begins with initiation, characterized by changes in gene expression and phenotype, making the cells responsive to cytokines and other stimuli. This is followed by perpetuation, where enhanced cytokine expression and ECM remodeling sustain the activated phenotype. Key mediators include transforming growth factor-β1 (TGF-β1), which is central to ECM production and stellate cell activation. TGF-β1 is increased in liver fibrosis and is involved in both the initiation and perpetuation of fibrosis. HSC activation leads to a series of phenotypic responses, including proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis, retinoid loss, and cytokine release. These responses are mediated by various signaling pathways, including those involving receptor tyrosine kinases, integrins, and the discoidin domain receptor (DDR2). The activation of HSCs is also influenced by changes in the ECM composition, which shifts from a basement membrane-like matrix to an interstitial matrix rich in fibril-forming collagens. During liver injury, HSCs migrate to areas of injury and contribute to the accumulation of scar tissue. The resolution of liver fibrosis involves the reversion of activated HSCs to a quiescent state or their clearance via apoptosis. Understanding the molecular mechanisms of HSC activation and resolution is crucial for developing therapeutic strategies to treat liver fibrosis. The study of HSCs provides a model for understanding how complex cellular events are integrated to achieve a distinct biological outcome, the encapsulation of tissue injury by scar.